A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

GLP-1 drugs are blockbuster medications for weight loss and Type 2 diabetes. Now doctors are trying them for lymphedema, ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

The drugmaker accuses Premier Weight Loss of risking patients' health by selling altered, unsterile versions of its ...

Lilly has already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products ...

Meanwhile, the first major obesity-related phase 3 trial for orforglipron is set to complete in July. If the data from the ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

INDIANAPOLIS — Eli Lilly and Company says it's suing an Indianapolis-based weight loss clinic that it claims is misleading patients about drugs being sold. Lilly claims Premier Weight Loss is ...